Hormonal
GLP-1 receptor agonists (semaglutide 2.4 mg and liraglutide 3 mg) produce significant body weight reduction (up to 20% with semaglutide) and improve cardiovascular risk factors, with semaglutide showing superiority in weight loss compared to previous drugs.
If lifestyle changes alone aren't enough, GLP-1 medications like semaglutide (2.4 mg weekly) are highly effective, producing up to 20% body weight loss in many patients. This weight loss is comparable to bariatric surgery and significantly improves blood pressure and cardiovascular risk. Discuss these options with your doctor if you have obesity and comorbidities.
Treatment with semaglutide produced a 5% reduction of body weight in >90% of subjects and a 20% reduction in about 35%, these results being comparable to those achieved with BMS.
Why this rating
Cites multiple large clinical trials (STEP, SCALE, SELECT) and meta-analyses.
Source
Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC)
Massimo Volpe et al. · Frontiers in Cardiovascular Medicine · 2023
DOI 10.3389/fcvm.2023.1136340
More from this paper
- Obesity is an independent, chronic non-communicable disease that directly causes cardiovascular disease through pathophysiological mechanisms including insulin resistance, endothelial dysfunction, and inflammation, rather than merely amplifying other risk factors.Strong
- Bariatric/metabolic surgery (BMS) is the most effective strategy for significant and sustained body weight reduction (14-25%) and reduces the risk of hypertension, diabetes, and mortality, but remains underused.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →